Provectus Biopharmaceuticals, Inc. (PVCT) stock
PVCTOTCPharmaceutical PreparationsFiscal year ends December 31
$0.05+0.00 (+0.39%)
Close on Oct 19, 2026Market cap $20.55MP/E –Yield –
Provectus Biopharmaceuticals operating margin
Operating margin is operating income as a percentage of revenue.
Provectus Biopharmaceuticals's operating margin for the twelve months ending Dec 31, 2025 was -1575.3%. For fiscal 2025 it was -1575.3%, against -734.4% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1575.3% | −840.9 |
| FY2024 | Dec 31, 2024 | -734.4% | −214.2 |
| FY2023 | Dec 31, 2023 | -520.2% | −173.6 |
| FY2022 | Dec 31, 2022 | -346.6% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2025 | Jun 30, 2025 | -3132.8% | −2821.1 |
| Q1 FY2025 | Mar 31, 2025 | -394.1% | −206.2 |
| Q4 FY2024 | Dec 31, 2024 | -16289.0% | −15789.7 |
| Q3 FY2024 | Sep 30, 2024 | -870.9% | +153.3 |
| Q2 FY2024 | Jun 30, 2024 | -311.7% | +182.7 |
| Q1 FY2024 | Mar 31, 2024 | -187.9% | +193.7 |
| Q4 FY2023 | Dec 31, 2023 | -499.3% | −84.5 |
| Q3 FY2023 | Sep 30, 2023 | -1024.1% | −812.6 |
| Q2 FY2023 | Jun 30, 2023 | -494.4% | −159.4 |
| Q1 FY2023 | Mar 31, 2023 | -381.5% | +151.5 |
| Q4 FY2022 | Dec 31, 2022 | -414.8% | – |
| Q3 FY2022 | Sep 30, 2022 | -211.6% | – |
| Q2 FY2022 | Jun 30, 2022 | -335.1% | – |
| Q1 FY2022 | Mar 31, 2022 | -533.1% | – |
See a number that looks wrong?